News headlines about C R Bard (NYSE:BCR) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. C R Bard earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.6032102045866 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

BCR has been the topic of a number of analyst reports. Barclays raised their target price on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. ValuEngine cut C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price on the stock in a research report on Tuesday, December 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $320.83.

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C R Bard has a 1-year low of $223.02 and a 1-year high of $337.73. The firm has a market capitalization of $24,140.00, a PE ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.

In related news, insider Jim C. Beasley sold 3,395 shares of C R Bard stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $332.00, for a total value of $1,127,140.00. Following the sale, the insider now directly owns 25,630 shares in the company, valued at approximately $8,509,160. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jim C. Beasley sold 15,044 shares of C R Bard stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $332.00, for a total value of $4,994,608.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,546 shares of company stock worth $10,826,150. 0.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “C R Bard (BCR) Given Daily Media Impact Score of 0.19” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with's FREE daily email newsletter.